Respuesta a las estatinas en prevención cardiovascular: evaluación de los hiporrespondedores

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Revista Argentina de Cardiología

• Publication date

  2014-02-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.7775/RAC.ES.V82.I1.2882
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Statins for the primary prevention of cardiovascular disease

  2014cited by this paper
• Trends in Low-Density Lipoprotein Cholesterol Goal Achievement in High Risk United States Adults: Longitudinal Findings from the 1999–2008 National Health and Nutrition Examination Surveys

  2013cited by this paper
• Achievement of Cardiometabolic Goals among Diabetic Patients in Spain. A Nationwide Population-Based Study

  2013cited by this paper
• Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)

  2012cited by this paper
• Efficacy of ezetimibe is associated with gender and baseline lipid levels in patients with type 2 diabetes.

  2012cited by this paper
• Genetic Determinants of Statin-Induced Low-Density Lipoprotein Cholesterol Reduction: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial

  2012cited by this paper
• Evidence for Cholesterol Hyperabsorbers and Hyperproducers Based on Comparative Low-Density Lipoprotein Reductions Achieved by Ezetimibe Versus Statins

  2012cited by this paper
• European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012)

  2012cited by this paper
• Demographic determinants of response to statin medications.

  2011cited by this paper
• Response by sex to statin plus ezetimibe or statin monotherapy: A pooled analysis of 22,231 hyperlipidemic patients

  2011cited by this paper
• Enteric Microbiome Metabolites Correlate with Response to Simvastatin Treatment

  2011cited by this paper
• Ongoing challenges in drug interaction safety: from exposure to pharmacogenomics.

  2010cited by this paper
• Major diet-drug interactions affecting the kinetic characteristics and hypolipidaemic properties of statins.

  2010cited by this paper
• Lipid‐altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high‐risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy – The IN‐CROSS study

  2009cited by this paper
• Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.

  2009cited by this paper
• Drug Class Review: HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin: Final Report Update 5

  2009cited by this paper
• Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism

  2009cited by this paper
• The validity of serum squalene and non-cholesterol sterols as surrogate markers of cholesterol synthesis and absorption in type 2 diabetes.

  2008cited by this paper
• The intestine as a regulator of cholesterol homeostasis in diabetes.

  2008cited by this paper
• Metabolomics: a global biochemical approach to drug response and disease.

  2008cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

  2007cited by this paper
• Analysis of Factors Associated With Statin Adherence in a Hierarchical Model Considering Physician,Pharmacy, Patient, and Prescription Characteristics

  2007cited by this paper
• Pharmacogenomics of statin response

  2007cited by this paper
• Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann–Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein

  2006cited by this paper
• Focus Issue: PROVE IT-TIMI 22Can Low-Density Lipoprotein Be Too Low? The Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein With Intensive Statin Therapy: A PROVE IT-TIMI 22 Substudy

  2005cited by this paper
• Adherence to medication.

  2005cited by this paper
• Initial low-density lipoprotein response to statin therapy predicts subsequent low-density lipoprotein response to the addition of ezetimibe.

  2004cited by this paper
• Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

  2003cited by this paper
• Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

  2003cited by this paper
• Why some patients respond poorly to statins and how this might be remedied.

  2002cited by this paper
• Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study

  1998cited by this paper
• Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.

  1996cited by this paper
• Cholesterol absorption and lipoprotein metabolism in type II diabetes mellitus with and without coronary artery disease.

  1996cited by this paper
• Genetic Determinants of Responsiveness to the HMG‐CoA Reductase Inhibitor Fluvastatin in Patients With Molecularly Defined Heterozygous Familial Hypercholesterolemia

  1993cited by this paper
• Expanded Clinical Evaluation of Lovastatin (EXCEL) Study Results: Effect of Patient Characteristics on Lovastatin‐Induced Changes in Plasma Concentrations of Lipids and Lipoproteins

  1992cited by this paper

• Ácido bempedoico en pacientes con diabetes tipo 2

  2022cites this paper
• Application of the individualized objectives defined by the European 2019 lipid guidelines in patients with type 2 diabetes

  2022cites this paper
• Bempedoic acid in patients with type 2 diabetes.

  2022cites this paper
• LDL Cholesterol Reduction Variability with Different Types and Doses of Statins in Monotherapy or Combined with Ezetimibe. Results from the Spanish Arteriosclerosis Society Dyslipidaemia Registry

  2021cites this paper
• Impact of statin therapy on LDL and non-HDL cholesterol levels in subjects with heterozygous familial hypercholesterolaemia.

  2021cites this paper
• Application of the individualized objectives defined by the European 2019 lipid guidelines in patients with type 2 diabetes.

  2021cites this paper
• Systematic Application of an Algorithm for Lipid Management in Cardiovascular High- Risk Patients. Impact on Lipid Goals

  2020cites this paper
• Percentage low-density lipoprotein-cholesterol response to a given statin dose is not fixed across the pre-treatment range: Real world evidence from clinical practice: Data from the ESC-EORP EUROASPIRE V Study

  2020cites this paper
• Response to statin therapy in the real world.

  2020cites this paper
• Impact of the 2019 European Guidelines on Diabetes in Clinical Practice: Real and Simulated Analyses of Lipid Goals

  2020cites this paper
• Lipid Goals in Diabetic Patients. Clinical Implications after Application of a New Formula for LDL-cholesterol Calculation

  2020cites this paper
• Análisis de Costo de la Enfermedad, del Tratamiento, las Complicaciones e Intervenciones de la Hipercolesterolemia en México en 2016.

  2018cites this paper
• Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER.

  2016cites this paper